R-propranolol is a small molecule inhibitor of the SOX18 transcription factor in a rare vascular syndrome and hemangioma
Propranolol is an approved non-selective β-adrenergic blocker that is first line therapy for infantile hemangioma. Despite the clinical benefit of propranolol therapy in hemangioma, the mechanistic understanding of what drives this outcome is limited. Here, we report successful treatment of pericard...
Main Authors: | Jeroen Overman, Frank Fontaine, Jill Wylie-Sears, Mehdi Moustaqil, Lan Huang, Marie Meurer, Ivy Kim Chiang, Emmanuelle Lesieur, Jatin Patel, Johannes Zuegg, Eddy Pasquier, Emma Sierecki, Yann Gambin, Mohamed Hamdan, Kiarash Khosrotehrani, Gregor Andelfinger, Joyce Bischoff, Mathias Francois |
---|---|
Format: | Article |
Language: | English |
Published: |
eLife Sciences Publications Ltd
2019-07-01
|
Series: | eLife |
Subjects: | |
Online Access: | https://elifesciences.org/articles/43026 |
Similar Items
-
Hemangioma infantil tratado com propranolol Propranolol treatment for hemangioma of infancy
by: Flavia Kakiuti Bonini, et al.
Published: (2011-08-01) -
Treatment of infantile hemangioma with propranolol
by: Gian Maria Pacifici -
Propranolol in the Treatment of Infantile Hemangiomas
by: Tan X, et al.
Published: (2021-09-01) -
Propranolol therapy for infantile hemangioma: our experience
by: Zhang L, et al.
Published: (2017-05-01) -
Oral Propranolol Administration in Treatment of Hemangiomas: An Update
by: Rahşan Özcan, et al.
Published: (2017-12-01)